Supporting independent medical education, contributing to advancements in medical and scientific research, and supporting initiatives that enhance both patient experiences and the diabetes care community.
Independent Educational Grants
Xeris Pharmaceuticals, Inc. is committed to supporting high-quality, unbiased, evidence-based independent medical education for the healthcare community. This medical education is fair-balanced, and is planned and implemented without influence from our industry or company.
Designed for healthcare professionals, patients, payers, and health systems, medical education should be developed to:
- Improve knowledge, increase understanding, and support behavioral change
- Close clinical and practice gaps
- Improve the quality and delivery of medical care for patients
To learn about submitting medical education grant requests to Xeris, please email: email@example.com
Investigator Initiated Studies (IIS)
Xeris is a specialty pharmaceutical company committed to developing medications and supporting research to address unmet medical needs. We are currently focused in the therapeutic area of severe hypoglycemia.
Severe hypoglycemia is an emergency condition where very low blood sugar may lead to confusion, seizure, unconsciousness, and if left untreated, death. It requires immediate treatment with fast-acting carbohydrates or the use of glucagon.
Glucagon, when used in the form of the traditional powder glucagon emergency kit, requires multiple steps to prepare and administer successfully. This may make it difficult for a patient to receive a full dose of glucagon in an emergency situation.
Development of patient and caregiver tools
We are dedicated to developing tools for those living with diabetes and their caregivers that simplify the administration of a full dose of glucagon — to immediately and successfully treat severe hypoglycemia.
Independent research reviews and support
We offer the opportunity for external researchers interested in conducting their own research related to our current therapeutic areas of interest to submit an independent research concept. The concept is then reviewed by an internal review committee. Xeris may provide funding and other resources, such as clinical trial material, to support studies initiated and sponsored by external researchers.
If you are interested in submitting a concept related to liquid stable, ready‑to‑use glucagon, please contact: firstname.lastname@example.org
Concepts will be prioritized based on scientific merit and relevance to the Xeris clinical and development program.
Learn more about the Xeris Expanded Access Program.
Xeris delivers innovative solutions to simplify the experience of administering important therapies that people around the world rely on every day.
We are focused on simplifying and making things better and easier. It’s about making a difference in people’s lives.
For more information on Xeris support and involvement with the Diabetes Camp communities, please contact us at: email@example.com
Xeris Pharmaceuticals is a supporter and corporate member of the Diabetes Education & Camping Association (DECA). More information about DECA can be found here: https://www.diabetescamps.org/
Contact Medical Affairs
For additional questions and/or clarifications, please contact Medical Affairs via 1‑844‑445‑5704 or firstname.lastname@example.org
To submit a product information question, report an adverse event, or submit a product complaint, please call 1‑877‑XERIS‑37 or email: email@example.com
We are proud to announce that as of October 5, 2021,
Xeris Pharmaceuticals, Inc. and Strongbridge Biopharma plc
are subsidiaries of Xeris Biopharma Holdings, Inc.
Not opening? Check to see you have pop-ups enabled or copy link below in a new window.https://ir.xerispharma.com/